Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease
Researchers identified a treatable autoimmune nerve condition that can mimic ALS, offering hope for patients previously thought to have untreatable motor neuron disease.
This multi-institutional discovery paper identifies septin multimers as novel autoantibody targets in severe motor neuropathy that can mimic ALS/lower motor neuron disease — a clinically critical distinction since autoimmune neuropathy is potentially treatable. Among 3,543 screened patients, 3 seropositive cases were identified with validated target specificity and histopathological evidence of myelin/axonal pathology; immunotherapy produced disease stabilization in one case.
What the study was
- Study design
- Autoantibody discovery study with retrospective validation cohort; mass spectrometry identification; cell-based assay validation; case series with 4-year clinical follow-up
- Population
- Patients with severe motor neuropathies mimicking LMND/ALS, screened via indirect immunofluorescence on murine teased sciatic nerve; multi-institutional (Charité Berlin, Mayo Clinic, Würzburg)
- Sample size
- 3543
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Brain
Why it surfaced
Novel autoantibody discovery in Brain (top neurology journal), multi-institutional, rigorous validation pipeline. Clinically impactful: distinguishing autoimmune treatable disease from fatal ALS is urgent. n=3 seropositive limits immediate clinical confidence, but discovery methodology is comprehensive. Rare disease watchlist cap exception explicitly applies (T9).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.